Key result
Tailoring dual-antiplatelet therapy using thromboelastography in patients undergoing Pipeline embolization resulted in 100% technical success, no hemorrhagic complications, and 89.5% occlusion at 1 year.
Why the study?
Does tailoring dual-antiplatelet therapy using thromboelastography improve safety and efficacy in patients undergoing intracranial aneurysm repair with the Pipeline embolization device?
Observational (n=31)
Does tailoring dual-antiplatelet therapy using thromboelastography improve safety and efficacy in patients undergoing intracranial aneurysm repair with the Pipeline embolization device?
Tailoring dual antiplatelet therapy using thromboelastography in patients undergoing Pipeline embolization for intracranial aneurysms altered management in 35% of cases and was associated with no hemorrhagic complications.
Authors
No takes yet. Share an insight, caveat, or question.
Supports safety of thromboelastography-tailored dual-antiplatelet therapy; leaves open need for randomized trials to confirm benefit in Pipeline embolization.
McTaggart et al. (2014) conducted an observational in Intracranial aneurysms (n=31). Thromboelastography (TEG)-tailored dual-antiplatelet therapy was evaluated on Technical success, thromboembolic/hemorrhagic complications, and angiographic occlusion. Tailoring dual-antiplatelet therapy using thromboelastography in patients undergoing Pipeline embolization resulted in 100% technical success, no hemorrhagic complications, and 89.5% occlusion at 1 year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: